Aris Angelis

Assistant Professor in Health Economics

London School of Hygiene & Tropical Medicine

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Aris Angelis is an Assistant Professor in Health Economics at the London School of Hygiene & Tropical Medicine, United Kingdom. His research primarily focuses on health technology assessment, with recent articles addressing topics such as composite endpoints in assessment practices, the Innovative Medicines Fund, and cost analyses related to health conditions such as dystrophic epidermolysis bullosa. Additionally, he explores the implications of health technology assessment methods for new therapies, including cell and gene therapies.

Articles (11)

Year:

2025

Year:

2025

Year:

2023

Year:

2023

Year:

2022

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (1)

Gilberto Montibeller

Professor of Management Science

Loughborough University

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Aris Angelis

Research Interests

Explore related searches

Contact this professor

About

Articles (11)

Composite endpoints in health technology assessment: Part 1 – an illustration of best modeling practice

Composite endpoints in health technology assessment: Part 2 – expanding the evidence base with a framework for best modeling practice

The Innovative Medicines Fund: a universal model for faster and fairer access to new promising medicines or a Trojan horse for low-value creep?

The success of NHS England’s Innovative Medicines Fund will depend on its operational details

Understanding the socioeconomic costs of dystrophic epidermolysis bullosa in Europe: a costing and health-related quality of life study

Multiple Criteria Decision Analysis for HTA across four EU Member States: Piloting the Advance Value Framework

Recalibrating Health Technology Assessment Methods for Cell and Gene Therapies.

Early Health Technology Assessment during Nonalcoholic Steatohepatitis Drug Development: A Two-Round, Cross-Country, Multicriteria Decision Analysis.

Early Health Technology Assessment during Nonalcoholic Steatohepatitis Drug Development: A Two-Round, Cross-Country, Multicriteria Decision Analysis

ICER Value Framework 2020 Update: Recommendations on the Aggregation of Benefits and Contextual Considerations.

Advancing structured decision-making in drug regulation at the FDA and EMA.

Collaborators (1)

Gilberto Montibeller

Make your next move.